COVID-19 Outcomes in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review

INTRODUCTION: Immune checkpoint inhibitors (ICIs) can cause inflammatory and immune-related adverse events (irAEs) that might worsen the course of COVID-19. We conducted a systematic review (PROSPERO ID: CRD42022307545) to evaluate the clinical course and complications of COVID-19 in patients with c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz, Juan I., Lopez-Olivo, Maria A., Geng, Yimin, Suarez-Almazor, Maria E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Innovative Healthcare Institute 2023
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195019/
https://www.ncbi.nlm.nih.gov/pubmed/37214207
http://dx.doi.org/10.36401/JIPO-22-24

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195019/
https://www.ncbi.nlm.nih.gov/pubmed/37214207
http://dx.doi.org/10.36401/JIPO-22-24

Ejemplares similares